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Purpose: Diffusion-weighted (DW) and dynamic contrast-enhanced magnetic resonance imaging
(MRI) are increasingly applied for the assessment of functional tissue biomarkers for diagnosis, lesion
characterization, or for monitoring of treatment response. However, these techniques are vulnerable
to the influence of various factors, so there is a necessity for a standardized MR quality assurance
procedure utilizing a phantom to facilitate the reliable estimation of repeatability of these quantitative
biomarkers arising from technical factors (e.g., B1 variation) affecting acquisition on scanners of
different vendors and field strengths. The purpose of this study is to present a novel phantom designed
for use in quality assurance for multicenter trials, and the associated repeatability measurements of
functional and quantitative imaging protocols across different MR vendors and field strengths.
Methods: A cylindrical acrylic phantom was manufactured containing 7 vials of polyvinylpyrroli-
done (PVP) solutions of different concentrations, ranging from 0% (distilled water) to 25% w/w, to
create a range of different MR contrast parameters. Temperature control was achieved by equilibration
with ice-water. Repeated MR imaging measurements of the phantom were performed on four clinical
scanners (two at 1.5 T, two at 3.0 T; two vendors) using the same scanning protocol to assess
the long-term and short-term repeatability. The scanning protocol consisted of DW measurements,
inversion recovery (IR) T1 measurements, multiecho T2 measurement, and dynamic T1-weighted
sequence allowing multiple variable flip angle (VFA) estimation of T1 values over time. For each
measurement, the corresponding calculated parameter maps were produced. On each calculated map,
regions of interest (ROIs) were drawn within each vial and the median value of these voxels was
assessed. For the dynamic data, the autocorrelation function and their variance were calculated; for
the assessment of the repeatability, the coefficients of variation (CoV) were calculated.
Results: For both field strengths across the available vendors, the apparent diffusion coefficient
(ADC) at 0 ◦C ranged from (1.12±0.01)×10−3 mm2/s for pure water to (0.48±0.02)×10−3 mm2/s
for the 25% w/w PVP concentration, presenting a minor variability between the vendors and the field
strengths. T2 and IR-T1 relaxation time results demonstrated variability between the field strengths and
the vendors across the different acquisitions. Moreover, the T1 values derived from the VFA method
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exhibited a large variation compared with the IR-T1 values across all the scanners for all repeated
measurements, although the calculation of the standard deviation of the VFA-T1 estimate across each
ROI and the autocorrelation showed a stability of the signal for three scanners, with autocorrelation
of the signal over the dynamic series revealing a periodic variation in one scanner. Finally, the ADC,
the T2, and the IR-T1 values exhibited an excellent repeatability across the scanners, whereas for the
dynamic data, the CoVs were higher.
Conclusions: The combination of a novel PVP phantom, with multiple compartments to give a
physiologically relevant range of ADC and T1 values, together with ice-water as a temperature-
controlled medium, allows reliable quality assurance measurements that can be used to mea-
sure agreement between MRI scanners, critical in multicenter functional and quantitative imaging
studies. C 2016 Author(s). All article content, except where otherwise noted, is licensed un-
der a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
[http://dx.doi.org/10.1118/1.4948997]
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1. INTRODUCTION
Magnetic resonance imaging (MRI) is a powerful noninvasive
imaging modality in oncology. Functional information on
tissue structure gained from diffusion-weighted (DW) and
dynamic contrast-enhanced (DCE) sequences is increasingly
used to yield observations beyond lesion size and location.
DW-MRI gives signal contrast derived from random motion
of water molecules in biological tissues and depends on
tissue structure; the derived apparent diffusion coefficient
(ADC) is also modulated by the presence of macromolecules,
interactions with cell membranes, and flow within vessels.1,2
The sensitivity of this technique to water diffusion properties
of tissue is generated by application of gradient pulses of
varying amplitudes, separations, and durations, summarized
by the parameter known as the b-value. In practice b-values
are selected not only by consideration of the anatomical region
being evaluated but also by the system capabilities and even
the investigator’s preferences.
DCE-MRI uses the kinetics of an administered exogenous
contrast agent to assess characteristics of tumor vasculature.
Pharmacokinetic modeling of the signal intensity curve over
repeated T1-weighted scans [utilizing a rapid T1-weighted
gradient-echo acquisition method as used for the variable flip
angle (VFA) measurements] with sufficient time resolution
following modeling gives parameters such as forward transfer
constant (K trans) and rate constant (kep) between extracellular
extravascular space and plasma, and fractional volumes of
extracellular extravascular space (ve) and blood plasma (vp)
per unit volume of tissue. Model-independent parameters can
also be obtained from the DCE-MRI measurement, such as
initial area under the gadolinium curve over 60 s after arrival
of contrast agent (IAUGC60) and the precontrast longitudinal
relaxation time (precontrast T1). Precontrast T1 is calculated
using the VFA method with one or more (precontrast) volume
from the dynamic scan and a matched volume acquired with
a distinct (usually lower) flip angle.3
Although DW-MRI (Refs. 4–6) and DCE-MRI are valuable
modalities in functional imaging,7–10 they are susceptible to
the influence of various factors including scanner type, field
strength, hardware specifications, and software implemen-
tation. Understanding the repeatability and the variability
of these measurements is critical if these modalities are
to be used in a quantitative manner for the prediction or
monitoring of treatment response in clinical trials, particularly
in pediatric trials where the relative rarity of disease requires
participation of multiple centers. A standardized MR quality
assurance procedure with a test object, or “phantom,” applied
to various scanners of different vendors and field strengths
with a repeatability estimate, would facilitate the reliable use
of these quantitative results as biomarkers.
An ideal phantom must provide reliable and reproduc-
ible multiparameter measurements without any temperature
dependence. Ideally, phantoms11 should be made of materials
that (a) provide values relevant to physiological ranges, (b) are
easily prepared, inexpensive, stable over time, and nontoxic,
and (c) provide reliable and reproducible values. There is
no currently available phantom that satisfies all of these
requirements. Pierpaoli et al.12 first introduced solutions of
polyvinylpyrrolidone (PVP) in water as potential phantoms for
DW-MRI measurements, though without temperature control.
PVP is an organic polymer, and by varying its concentration
in solution, a range of desirable T1 and ADC values can
be created without the addition of any paramagnetic metal
ions. Additionally, PVP solutions are known to be chemically
stable over a long period of time, in contrast to the sucrose
solutions previously used for quality assurance of diffusion
measurements.13,14 Malyarenko et al.15 used ice-water as a
universal temperature control fluid in diffusion measurements,
removing the need to adjust for the known temperature
dependence ofT1 and ADC values. Subsequently, Boss et al.16
proposed an ice-water temperature-controlled phantom with
PVP solutions for the quality assurance of diffusion measure-
ments providing reliable and repeatable values relevant to
the physiological range. For DCE-MRI, different dynamic
phantoms have been presented for specific applications;17 a
general-purposed phantom providing a physiological range
of T1 values for assessment of stability with controlled
temperature would be ideal for deriving comparative metrics
across different MR vendors.
A standardized MR quality assurance procedure, combin-
ing a protocol for performing multiple functional MRI
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measurements (like DW and DCE-MRI) in a limited time
with a well-designed phantom of multiple temperature-
controlled solutions with a suitable range of multiple MR
contrast parameters, will provide a valuable resource for
multicenter imaging protocol development and optimization
within multicenter trials. The aim of this study is therefore to
present such a phantom and the repeatability measurements
of functional, DW and DCE-MRI, and quantitative T1 and
T2, imaging protocols across different MR vendors and field
strengths as a quality assurance tool in multicenter clinical
trials.
2. MATERIALS AND METHODS
2.A. Phantom preparation
Polyvinylpyrrolidone [PVP, (C6H9NO)x, Sigma-Aldrich]
with a mean molar mass of 55 000 g/mol was used for the
generation of gels with different MR characteristics. Materials
for construction of the phantom are inexpensive and readily
available, and construction itself is approximately one day’s
labor. PVP in powder form was dissolved in 320 ml of
distilled water inside a water bath in order to prepare the
mixture under constant temperature conditions (55 ◦C). The
solution was continuously stirred until the PVP was fully
dissolved and then left in the water bath for 45 min to stabilize,
before being removed and left to cool to room temperature
(18 ◦C). Different amounts of this stock solution were diluted
in distilled water for the production of PVP concentration
solutions ranging from 2.5% to 25% w/w. Each solution was
degassed using He in order to remove any dissolved oxygen.
All the solutions were produced under the same conditions, to
reduce systematic error on the MR measurements. In the initial
preparation, containing only PVP and distilled water, bacterial
growth was observed four months following production; the
whole procedure was thus repeated with the inclusion of
sodium azide (5 mg) to the initial PVP mixture to prevent
this growth. The different concentrations were transferred to
60 ml vials (diameter 27 mm), and these were sealed using
their appropriate caps and paraffin film.
Six different PVP solutions with concentrations 2.5%,
5%, 10%, 15%, 20%, and 25% w/w, together with one vial
containing distilled water (0%, with sodium azide) and a
localization rod were fixed inside a custom-built cylindrical
acrylic phantom, with an inner diameter of 18 cm and height
of 19 cm. The vial with the distilled water was positioned
in the center of the phantom and the PVP vials arranged
such that when viewed axially, PVP concentration decreased
counterclockwise (Fig. 1).
Temperature control of the phantom was achieved by filling
the cylinder with ice-water 1 h before scanning. Following a
45-min equilibration time, more ice was added to replenish
the amount melted. Before transferring the phantom to the
MR scanner room, the temperature was measured to verify
that the phantom contents were at 0 ◦C.
2.B. MRI acquisition
MR imaging measurements were performed on four
clinical scanners, two at 1.5 T, denoted scanners A (MAG-
NETOM Avanto, Siemens Healthcare, Erlangen, Germany)
and B (MAGNETOM Aera, Siemens Healthcare, Erlangen,
Germany) and two at 3.0 T, denoted C (MAGNETOM
Skyra, Siemens Healthcare, Erlangen, Germany) and D
(Achieva, Philips Healthcare, Best, The Netherlands), us-
ing the appropriate modified protocol for each case. The
scanning protocol included DW-MRI, inversion recovery T1
measurements (IR-T1), a multiecho T2 measurement, and a
dynamic scan as used for DCE-MRI allowing variable flip
angle estimation of T1 (VFA-T1) with successive dynamic
volumes. The scanning parameters for these scans on each
system are presented in Tables I–IV. For DW-MRI, four
separate successive measurements were acquired and stored
separately to avoid signal averaging in the scanner and allow
investigation of measurement stability. The flip angles for
the VFA measurement were determined as optimal for the
expected range of T1 (500–1400 ms) in the phantom at
1.5 T.18,19
The phantom was placed on the scanner bed with its central
axis parallel to the z-axis of the magnet for axial image
F. 1. Phantom construction with PVP gels (left), calculated axial T2 map (center, T2 range from 510 to 1406 ms), and calculated axial T1 map (right, T1 range
from 520 to 1415 ms) of the phantom at 1.5 T with the selected ROIs with corresponding PVP concentrations are given in % w/w.
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T I. Sequence parameters for acquisition of diffusion-weighted imaging measurements.
A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)








Coil Body array coil Body array coil Body array coil Torso coil
Number of slices 5 5 5 5
Slice thickness (mm) 5 5 5 5
Gap slice (mm) 0 0 0 0
Orientation Axial Axial Axial Axial
FoV (mm) 320 × 280 320 × 280 320 × 260 320 × 320
Acquired matrix 128 × 112 128 × 112 128 × 104 128 × 128
Reconstructed matrix 256 × 224 256 × 224 256 × 208 128 × 128
Parallel imaging GRAPPA GRAPPA GRAPPA SENSE
PE direction Right–left Right–left Right–left Right–left
TR (ms) 8000 8000 8000 8000
TE (ms) 76 76 76 76
b (mm−2s) 0, 100, 500, 900 0, 100, 500, 900 0, 100, 500, 900 0, 100, 500, 900
Diffusion gradient mode 3 scan trace 3 scan trace 3 scan trace Gradient overplus
Receiver bandwidth (Hz/pixel) 1776 1775 1775 2996
NSA 4 (separate) 4 (separate) 4 (separate) 4 (separate)
Fat-suppression technique SPAIR SPAIR SPAIR SPAIR
acquisition. To ensure the reproducible positioning of the
phantom on the bed across the repeatable measurements, the
internal localization rod was used as a localization reference.
A plastic wedge was used to slightly raise one end of the
phantom, in order to force any bubbles to the top of the phan-
tom and remove them from the field of view (FoV). The
phantom was scanned three times on each scanner in separate
imaging sessions to assess both long-term and short-term
repeatability of DW, DCE, T1, and T2 measurements, using
paired scans separated by approximately 1 month and 2–24 h
(with complete removal and repositioning of the phantom and
routine scanning performed in between), respectively. In each
case, the scanning duration was 50 min, during which period
the temperature of the phantom components was between 0
and 1 ◦C.
2.C. Data analysis
All calculations of functional parameters were performed
on a voxel-by-voxel basis, with no image smoothing, using
in-house software (ADEPT and MRIW, Institute of Cancer
Research, London). For all calculated parameter maps, large
circular regions of interest (ROIs) (area 138–250 mm2) were
drawn within each vial in the phantom, and the median value
for the voxels in each ROI recorded. ADC and T2 maps were
calculated using a monoexponential model for all b-value and
echo time images, respectively [Eqs. (1) and (2)].T1 maps were
calculated using the images acquired at different inversion
times (IR-T1) according to Eq. (3) (valid given the long TR of
10 s) and then separately using the variable flip angle method,
using a combination of the multiple-averaged data at low flip
T II. Sequence parameters for acquisition of inversion recovery T1 (IR-T1) measurements.
A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
Sequence Turbo flash Turbo flash Turbo flash Turbo flash
Coil Body array Body array Body array Torso
Number of slices 1 1 1 1
Slice thickness (mm) 8 8 8 8
Orientation Axial Axial Axial Axial
FoV (mm) 300 × 300 300 × 300 300 × 300 300 × 300
Acquired matrix 128 × 102 128 × 102 128 × 102 120 × 120
Reconstructed matrix 128 × 128 128 × 128 128 × 128 128 × 128
TR (ms) 10 000 10 000 10 000 10 000
TE (ms) 1.2 1.2 1.2 1.6
Receiver bandwidth (Hz/pixel) 488 490 490 479
NSA 1 1 1 1
Fat-suppression technique Inversion recovery Inversion recovery Inversion recovery Inversion recovery
Inversion times (s) 0.11, 0.3, 0.4, 0.5, 0.7, 0.9, 1.1,
1.3, 1.5, 2, 2.5, 3, 3.5, 4, 4.5
0.11, 0.3, 0.4, 0.5, 0.7,
0.9, 1.1, 1.3, 1.5, 2,
2.5, 3, 3.5, 4, 4.5
0.11, 0.3, 0.4, 0.5, 0.7,
0.9, 1.1, 1.3, 1.5, 2,
2.5, 3, 3.5, 4, 4.5
0.15, 0.3, 0.4, 0.5, 0.7, 0.9, 1.1,
1.3, 1.5, 2, 2.5, 3, 3.5, 4, 4.5
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T III. Sequence parameters for acquisition of variable flip angle T1
(VFA-T1) measurements.
A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
Type of sequence 3D flash 3D flash 3D flash Spoiled 3D
GRE
Coil Body array Body array Body array Torso
Number of slices 14 18 18 14
Slice thickness (mm) 5 5 5 5
Orientation Axial Axial Axial Axial
FoV (mm) 301 × 301 230 × 230 280 × 227 350 × 350
Acquired matrix 128 × 96 128 × 83 128 × 84 128 × 130
Reconstructed matrix 128 × 96 128 × 128 128 × 104 128 × 130
TR (ms) 3.00 3.32 3.32 3.70
TE (ms) 0.91 0.71 0.75 1.723
Receiver bandwidth
(Hz/pixel)
651 600 600 498
NSA: static, dynamic 10, 80 × 1 4, 80 × 1 4, 80 × 1 10, 80 × 1
Flip angles (deg) 2, 11 2, 11 2, 11 2, 11
angle with each of the images in the dynamic series at higher
flip angle (VFA-T1) according to Eq. (4),




























To confirm good signal-to-noise ratios (SNRs) for derived
parameters from the diffusion-weighted and T2-weighted
measurements, SNRs were estimated for the vial with the
largest ADC at highest b-value and for the vial with the
shortest T2 at longest echo for the 4 scanners using the average
signal within the ROI divided by the variance of noise from a
corresponding region ROI positioned in empty space (devoid
of artefacts) on the same image.
From the dynamic data, it is also possible to calculate
the autocorrelation (AC) function for each T1 measurement
to its successive measure, as well as the variance of the T1
measurement across the whole dynamic series, yielding the T1
















where σT1 and σS are the standard deviations (s.d.) of T1 and
the signal, respectively, S0 is the initial signal intensity, and
TS is the total scan time.
2.D. Statistical analysis
The short-term and long-term repeatability of each MR
contrast parameter were assessed using the repeated measure-
ments coefficient of variation (CoV, expressed as percentage)
between the second and the third imaging session (time
separation between 2 and 24 h, with complete removal and
repositioning of the phantom) and between the first and the
second imaging session (time separation more than 1 month),
respectively. For the calculation of the CoVs, a log-normal
distribution was assumed and logarithms of the parameters
were used when calculating the various statistics.22,23 First,
the sample variance (V ) of the logarithmic difference of the
two compared imaging sessions were calculated, and then the










3.A. Apparent diffusion coefficient values
For each vendor, four individual diffusion-weighted
measurements were acquired, the SNR of the highest b-
T IV. Sequence parameters for acquisition of T2 measurements.
A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
Type of sequence Multiple spin echo Multiple spin echo Multiple spin echo Multiple spin echo
Coil Body array Body array Body array Torso
Number of slices 1 1 1 1
Slice thickness (mm) 8 8 8 8
Orientation Axial Axial Axial Axial
FoV (mm) 300 × 262 300 × 262 300 × 262 300 × 300
Acquired matrix 128 × 112 128 × 112 128 × 112 120 × 120
Reconstructed matrix 256 × 224 256 × 224 256 × 224 224 × 224
TR (ms) 4000 4000 4000 4000
TE (ms) 13.1, 26.2, 39.3, . . . , 419.2
(32 values)
13.1, 26.2, 39.3, . . . , 419.2
(32 values)
13.1, 26.2, 39.3, . . . , 419.2
(32 values)




130 130 130 1620
NSA 1 1 1 1
Medical Physics, Vol. 43, No. 6, June 2016
3003 Jerome et al.: Temperature-controlled quality assurance phantom for functional quantitative MRI 3003
F. 2. Representative ADC maps for each scanner, A and B at 1.5 T and C and D at 3.0 T. The calculated values of ADC showed excellent repeatability and
reproducibility across scanners.
value image on the central vial (0% w/w PVP solution)
was estimated [ranged from 147.2 to 3155.8 (signal/noise)],
and the mean voxel signal intensity at each voxel for all
images for each b-value was calculated for the production of
the ADC maps (Fig. 2). As presented in Table I, the field
of view of scanner D was different to the other scanners,
reflecting current clinical protocol variation. The ADC values
of each vial were estimated using each of the four individual
measurements (nonaveraged, acquired within a single imaging
session) and using the mean of these measurements. The per-
centage deviations of the ADC estimates in each vial between
the mean and each individual measurement were less than
1%, indicating low intrinsic measurement noise. Moreover,
the percentage deviations between the ADC estimates of each
slice and the corresponding estimates of all the slices were also
less than 1%, showing negligible variation through the slices.
Consequently, the ADC values reported are the mean values
at each of the four acquisitions (nonaveraged measurements)
on each scanner for one imaging session, from the central
slice (Table V). At both 1.5 and 3.0 T across both vendors,
the ADC values ranged from (1.12± 0.01)× 10−3 mm2/s
for pure water to (0.48± 0.02)× 10−3 mm2/s for the 25%
w/w PVP concentration, exhibiting an anticipated decrease
with the increase in PVP concentration. The differences in
ADC values between the vendors and the field strengths were
small.
3.B. IR-T1 and T2 relaxation times
The mean calculated IR-T1 and T2 relaxation times of
each vial are presented in Tables VI and VII. In both cases,
the relaxation times varied across the different acquisitions
showing some variance with field strength and vendor,
although generally a good agreement was found across the
scanners for each gel concentration. T2 relaxation times
derived from 1.5 T data showed variation when compared
to the corresponding values from 3.0 T data, whereas for
the majority of the vials, the IR-T1 relaxation times at 3.0 T
demonstrate an increasing T1 as compared to the 1.5 T
T V. ADC (×10−3 mm2/s) estimates (median ± s.d. of each ROI mean)
of each PVP solution across the different scanners.
ADC (×10−3 mm2/s)
PVP concentration
(% w/w) A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
0 1.12 ± 0.01 1.11 ± 0.02 1.12 ± 0.01 1.11 ± 0.01
2.5 1.05 ± 0.02 1.04 ± 0.02 1.08 ± 0.02 1.04 ± 0.01
5 0.98 ± 0.02 0.98 ± 0.01 1.01 ± 0.02 0.95 ± 0.01
10 0.85 ± 0.01 0.86 ± 0.01 0.86 ± 0.01 0.82 ± 0.01
15 0.71 ± 0.01 0.72 ± 0.02 0.71 ± 0.01 0.71 ± 0.01
20 0.59 ± 0.02 0.59 ± 0.01 0.59 ± 0.01 0.59 ± 0.01
25 0.50 ± 0.02 0.49 ± 0.01 0.49 ± 0.02 0.48 ± 0.02
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T VI. IR-T1 (ms) relaxation times (median ± s.d. of each ROI) of each
PVP solution using the inversion recovery measurement across the different
scanners.
IR-T1 (ms)PVP concentration
(% w/w) A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
0 1415 ± 19 1520 ± 26 1562 ± 17 1488 ± 28
2.5 1398 ± 24 1380 ± 24 1449 ± 11 1376 ± 22
5 1313 ± 13 1251 ± 21 1328 ± 14 1252 ± 21
10 1098 ± 15 1041 ± 26 1105 ± 13 1073 ± 15
15 879 ± 16 872 ± 15 913 ± 13 905 ± 13
20 664 ± 14 688 ± 14 761 ± 15 745 ± 11
25 523 ± 15 543 ± 16 609 ± 18 612 ± 13
values. The SNR of the T2-weighted images was estimated
by drawing an ROI on the vial with the shortest T2 within
the longest-TE image and was found to be satisfactory at
492–1960 (signal/noise).
3.C. VFA-T1 and dynamic measurement stability
The T1 values derived from the VFA method, VFA-T1,
are presented in Table VIII and show a large variation
from those derived by the (gold-standard) inversion recovery
method, with larger variance across scanners as well as
for repeated measurements on each scanner. Scanner C
gives consistently higher T1 estimates for VFA than for
IR-T1, with the other scanners in general agreement. The
standard deviation seen in the VFA-T1 estimate across each
individual ROI, Table IX, are relatively small, indicating a
stable dynamic series of images, with the main source of
variation being in T1 estimation across separate scanning
sessions. In all cases, the average mean/(standard deviation)
of each T1 estimate within the ROIs was greater than 20
(Table X).
The next-value autocorrelation of the dynamic series,
measuring stability of the signal over the dynamic time
course, was observed to be close to 0 (range −0.06 to
0.02) for all PVP concentrations in three out of four
scanners, with the final scanner (Scanner D, 3.0 T) returning
values consistently higher and indicating instability in the
signal over time (Table XI). Examination of one such
T VII. T2 (ms) relaxation times (median ± s.d. of each ROI) of each PVP
solution in the phantom measured across the different scanners.
T2 (ms)PVP concentration
(% w/w) A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
0 1403 ± 3 1417 ± 5 1511 ± 11 1433 ± 11
2.5 1281 ± 2 1334 ± 6 1396 ± 10 1323 ± 8
5 1277 ± 8 1201 ± 4 1247 ± 10 1171 ± 4
10 1046 ± 3 984 ± 2 985 ± 4 941 ± 4
15 841 ± 3 811 ± 3 791 ± 5 760 ± 6
20 638 ± 4 661 ± 3 638 ± 7 608 ± 6
25 512 ± 4 526 ± 4 509 ± 5 490 ± 7
T VIII. Mean VFA-T1 (ms) relaxation times (median ± s.d. of each ROI)
of each PVP solution calculated across the dynamic series.
Mean VFA-T1 (ms)PVP concentration
(% w/w) A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
0 1520.4 ± 311 1732.6 ± 29 2344.7 ± 330 1466.4 ± 166
2.5 1217.1 ± 224 1394.5 ± 59 1759.5 ± 165 1108.2 ± 145
5 990.6 ± 166 1214.5 ± 46 1538.8 ± 173 1050.6 ± 141
10 762.7 ± 139 866.1 ± 9 1163.7 ± 122 886.5 ± 91
15 611.1 ± 74 638.9 ± 2 961.5 ± 86 710.4 ± 85
20 478.9 ± 15 500.4 ± 7 724.2 ± 72 569.4 ± 87
25 399.7 ± 32 412.4 ± 12 576.0 ± 32 459.6 ± 85
example reveals a periodic variation in signal of around 15%
(Fig. 3), and the correlogram shows a clear periodicity of
around 38 s.
3.D. Repeatability measurements
The short-term and long-term repeatability estimates,
assessed by calculating of the coefficient of variation for
each case, are given for each parameter in Table XII.
Excellent repeatability of 5% or lower, often below 1%, was
observed across all scanners for both long-term and short-term
comparisons of ADC, T2, and IR-T1 values. The short-term
repeatability was almost always better than the long-term for
these parameters.
Parameters derived from the dynamic data show consis-
tently higher CoV, with values as high as 17% and 10% for
long-term and short-term repeatability, respectively. While
short term CoVs are generally smaller than long-term, the
difference is often minor and suggests no fundamental
difference from repetitions of measurements on the different
timescales. Moreover, for each vendor the dependence of the
ADC estimates with the morning and afternoon session was
estimated in order to investigate any effect related to the
time of the scanning session. In all cases, the ADC CoVs
between the morning and the afternoon measurement were
less than 2%.
T IX. Median standard deviations with the standard deviation of each
calculation of VFA-T1 relaxation times in each ROI across the dynamic
series.
Median standard deviations of VFA-T1PVP concentration
(% w/w) A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
0 64.1 ± 23 65.6 ± 2 50.5 ± 22 30.8 ± 6
2.5 38.6 ± 19 43.0 ± 2 34.6 ± 20 19.9 ± 4
5 26.4 ± 14 24.2 ± 1 26.0 ± 17 17.0 ± 3
10 17.8 ± 9 17.9 ± 2 18.3 ± 12 12.7 ± 1
15 15.4 ± 3 12.6 ± 1 16.8 ± 11 10.5 ± 2
20 10.3 ± 1 7.1 ± 1 12.6 ± 8 8.7 ± 2
25 8.6 ± 0 6.1 ± 1 10.3 ± 7 7.3 ± 2
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T X. Mean/standard deviation with the standard deviation of each cal-
culation for T1 relaxation times derived from VFA method.
Mean/standard deviation
PVP concentration
(% w/w) A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
0 24.7 ± 3.3 26.1 ± 0.7 53.1 ± 23.5 48.9 ± 9.4
2.5 37.3 ± 12.3 32.4 ± 1.5 62.6 ± 30.4 58.5 ± 15.4
5 41.7 ± 12.3 50.1 ± 0.4 76.2 ± 41.0 64.0 ± 12.2
10 46.8 ± 11.7 48.9 ± 5.9 81.8 ± 42.0 70.3 ± 9.1
15 39.8 ± 2.8 51.5 ± 3.6 73.7 ± 38.1 68.0 ± 13.6
20 47.0 ± 5.2 72.3 ± 9.2 73.9 ± 39.7 67.5 ± 18.9
25 44.1 ± 2.6 70.8 ± 8.1 72.6 ± 38.2 67.1 ± 18.5
4. DISCUSSION
This study presents a new phantom containing multiple
compartments of PVP solutions at ice-water temperatures
for the quality assurance of functional and quantitative
imaging across different MRI platforms. The preparation
of PVP solutions at different concentrations provides a
physiologically relevant range of ADC andT1 values, and with
a range of T2 values that can be measured to assess reliability,
repeatability, and reproducibility in a multicenter setting
using a standardized acquisition. The design of the phantom
combines the features of existing alternative phantoms,
including a chemically stable gel with user-modifiable MR
properties, multiple compartments allowing the coverage of
a wide MR parameter range, and known and reproducible
temperature, to create a new phantom with all the conferred
advantages.
There are several limitations in this study; first, scanners
from only two different vendors were used, and this could be
usefully expanded in future studies. Second, measurements
were performed at both field strengths only for one vendor,
allowing investigation of the influence of field strength only
for this particular vendor. Finally, the DCE-MRI protocols in
this study are not directly comparable, each implementation
being a typical protocol for that platform, and thus allowing
only assessment of their repeatability and variability. While
this is not ideal, the primary scope of this study is not
T XI. Autocorrelation with the standard deviation of each calculation of
dynamic data signal intensity with succeeding point.
AutocorrelationPVP
concentration
(% w/w) A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
0 −0.03 ± 0.024 −0.06 ± 0.001 0.02 ± 0.022 0.29 ± 0.199
2.5 −0.05 ± 0.008 −0.04 ± 0.026 −0.02 ± 0.025 0.26 ± 0.260
5 −0.01 ± 0.024 −0.05 ± 0.024 −0.02 ± 0.030 0.33 ± 0.150
10 −0.03 ± 0.039 −0.05 ± 0.025 −0.02 ± 0.024 0.25 ± 0.191
15 −0.01 ± 0.017 −0.05 ± 0.013 −0.02 ± 0.075 0.23 ± 0.138
20 0.01 ± 0.008 −0.02 ± 0.041 0.01 ± 0.028 0.33 ± 0.283
25 −0.01 ± 0.014 −0.10 ± 0.014 0.00 ± 0.015 0.31 ± 0.179
to compare scanner performance, but the presentation of
a phantom for the quality assurance of functional and
quantitative imaging protocols allowing assessment of their
reproducibility across multicenter studies.
The ADC values of this phantom are consistent with a
variety of biological tissues (brain, bone marrow, and tumor),
delivering a relevant physiological range, although the ADC
range available is limited by the temperature control at 0 ◦C,
and some tissues have larger ADC values (e.g., kidney). The
excellent repeatability of the ADC measurements for both long
and short term, assessed via calculation of the CoVs, indicates
a reliable quality assurance procedure. Previous published
repeatability of ADC measurements in phantoms12,15,16,24,25
are in agreement with our values.
The calculated ADC values across the MR scanners
depicted differences between the vendors, in line with another
phantom study.25 In contrast to the study by Lavdas et al.25
the ADC values reported in this study did not show any
dependence with the field strength; the use of 7 different
solutions in this study, compared to only 3, increases the
confidence of the comparison. Malyarenko et al.15 report
repeatability and reproducibility of a single ADC value in an
ice-water phantom across different vendors and field strengths.
With 3.0 T MR scanners becoming increasingly common,
the utilization of a standardized quality assurance procedure
across scanners of different field strength and vendor is crucial
F. 3. Signal intensity trace within the 0% PVP vial (voxel locations shown inset), showing (a) unstable (scanner D) and (b) stable (scanner B) behavior;
correlogram of scanner D data in (c) shows a periodicity of around 38 s.
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T XII. Coefficients of variations (%) for all derived parameters in each MRI scanner.
A (1.5 T) B (1.5 T) C (3.0 T) D (3.0 T)
Long-term Short-term Long-term Short-term Long-term Short-term Long-term Short-term
ADC 0.9 1.1 1.3 0.7 1.1 0.4 1.1 1.0
T2 5 0.6 0.6 0.2 0.3 0.3 0.3 0.5
IR-T1 1.2 0.3 1.0 1.0 0.4 0.4 0.6 0.6
VFA-T1 mean 7.51 0.74 2.23 1.63 3.49 2.47 3.52 4.47
VFA-T1 mean/s.d. 16.91 6.10 8.65 6.36 7.29 5.77 11.76 8.71
AC 2.71 2.82 3.18 2.61 3.80 4.55 11.12 6.89
T1 NF 6.69 0.47 1.68 1.07 3.56 2.21 1.46 2.28
T1 SNR 15.74 2.28 9.89 7.70 7.40 5.40 10.66 9.32
for quality assurance in multicenter studies. In this study, not
only repeatable DW measurements of multiple temperature-
controlled solutions were presented but also quantitative T1,
T2, and DCE-MRI measurements across two different vendors
and field strengths.
The estimated values for IR-T1 and T2 relaxation times
were comparable with the corresponding values of biological
tissues and fluids, respectively.26 It is both practical and
convenient to acquire the T1 and T2 measurements under the
same temperature control as required for reliable estimation
of ADC, since these are also known to be sensitive to
temperature.27,28 It is worth noting that T1 values showed a
dependence on the field strength, of approximately 40 ms/T
for all vials (calculated as the average difference across
field strengths for all the scanners), and this result is in
agreement with the documented increase inT1 values observed
at 3.0 T by De Bazelaire.26 Moreover, the good short-term and
long-term repeatability (less than 5%) of these parameters
using the protocol described demonstrates the reliability and
repeatability of these measurements with this phantom.
Parameters derived from the dynamic scans, as used for
DCE-MRI measurements, clearly demonstrate the difficulty
with estimation of T1 relaxation times using the variable
flip angle measurements29 and suggest that such data may
only reliably provide relative T1 values. The two-point VFA
measurement works well for a single TR/T1 combination,3
but there is an inherent difficulty in accurate T1 determination
across a range of T1 values; a multiple-flip angle measurement
has been shown to improve T1 accuracy but only at the
expense of time.30,31 In the context of biomarkers for response,
however, repeatability and stability of measurements are
critical in being able to confidently identify changes in T1
relaxation times, in clinical applications where the change
may be small. The autocorrelation functions for the dynamic
data showed acceptable stability across the varying PVP
concentrations (with corresponding T1 range) for all scanners
over the acquisitions, with the exception of one scanner where
the quality assurance procedure identified a periodic signal
variation that would compromise the DCE-MRI study, which
was not observed from a simple examination of T1 standard
deviation across the series. The CoV of dynamic parameters
were consistently higher than those for ADC, IR-T1 values, and
T2, which reflects the compromise in data quality necessary
when acquiring at high temporal resolution, though the CoVs
returned were shown to be acceptable (<10%) for both long-
term and short-term repeatability.
In conclusion, the combination of a novel PVP phantom,
with multiple compartments to give a physiologically relevant
range of ADC and T1 values, together with the simplicity
and reproducibility of ice-water temperatures, allows reli-
able quality assurance measurements that can be used to
measure agreement of MR scanners, which will be critical
in the context of multicenter functional imaging studies
that contain diffusion-weighted imaging, dynamic contrast-
enhanced imaging, and T1 and T2 measurements.
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